DUBLIN, August 22, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global DNA Vaccine Market Outlook 2022" report to their offering.

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. Various vaccines have been introduced in the market based on this technique.

Some of the major DNA vaccines include GlaxoSmithKline's Engerix-B, Twinrix, and Fendrix; Merck's Gardasil, and Recombivax HB; Protein Sciences Corporation's Flublok, etc. Currently, the researchers are engaged in developing genetic vaccines for humans. Animal genetic vaccines are already present in the market. These vaccines are third generation vaccines, and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response.

This comprehensive report provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry. The study has publicized that though the numbers of DNA vaccines that target the human clinical segment are relatively fewer in number, however due to high sales of these vaccines, the DNA vaccine market is estimated to reach US$ 7 Billion by the end of 2016.

The report also contains detailed and in-depth analysis of the segmentation of the DNA vaccines market based on types of DNA vaccines, therapeutic indication, end-users, and geography. Based on the type, the DNA vaccines market is divided into recombinant protein and genetic. In 2016, recombinant protein segment is estimated to account for largest share in the market. This large share is attributed to the presence of high number of recombinant protein vaccines in the market.

Major players in the DNA Vaccines market are also profiled with company overview, financial overview, product portfolios, recent developments, and strengths and weaknesses. The last section of the report discusses about the recommendations which could help the DNA vaccine market grow at a faster pace. Conclusively, the research will prove to be a useful resource for all debut makers in DNA vaccine industry, and potential investors.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. DNA Vaccine - An Introduction

4. Drivers & Challenges

4.1 Drivers

4.1.1 Increasing Investment

4.1.2 Advantages of DNA Vaccines over Traditional Vaccines

4.1.3 Dramatic Increase in Chronic Disorders

4.1.4 Strong DNA Vaccine Pipeline

4.1.5 Technological Advancements

4.2 Challenges

4.2.1 Uncertainty in Regulatory System

4.2.2 Lack of Awareness in Developing Countries

4.2.3 Development Limited to Plasmid Vectors

5. DNA Vaccine Market Overview

6. DNA Vaccines Market by Geography

6.1 North America

6.2 Europe

6.3 Asia Pacific

7. DNA Vaccine Market by Type

7.1 Recombinant Protein Vaccines

7.1.1 By Geography (North America, Europe, Asia Pacific)

7.2 Genetic Vaccines

7.2.1 By Geography (North America, Europe, Asia-Pacific)

8. DNA Vaccines Market by End User

8.1 Human

8.2 Animal

9. DNA Vaccines Market by Therapeutic Indication

9.1 Infectious & Vector Borne Diseases

9.2 Cancer

10. Pipeline Analysis

11. Trends

11.1 Increasing Focus on Genetic Vaccine Development

11.2 Expanding Applications Increasing Popularity of DNA Vaccines

11.3 Partnerships Enhancing Genetic Vaccines Development

12. Company Profiles

12.1 Novartis International AG

12.2 Merck & Co., Inc

12.3 GlaxoSmithKline plc.

12.4 Sanofi

12.5 Zoetis

12.6 Green Cross Corporation

12.7 Inovio Pharmaceuticals, Inc.,

12.8 Bharat Biotech

12.9 Protein Sciences Corporation

12.10 Indian Immunologicals Ltd.

12.11 Serum Institute of India Pvt. Ltd

13. Recommendations

For more information about this report visit http://www.researchandmarkets.com/research/2jvkcm/global_dna

Related Topics: Vaccines

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets